October 7, 2020 -- Centaur Biopharmaceutical Services has expanded its manufacturing agreement with Vaxart to manufacture Vaxart's oral COVID-19 vaccine.
As a contract development and manufacturing organization, Centaur will provide its expertise in protein-based biologics and virus-based product manufacturing. The company, a subsidiary of KindredBio, has facilities in California and Kansas.
Under the terms of the extended agreement, Centaur will be responsible for scaling the COVID-19 clinical trial material into mid-size bioreactors at its California plant, and manufacturing at 2000-L scale in single-use bioreactors at its Kansas plant.
Vaxart received investigational new drug application clearance for its phase I clinical trial evaluating its oral COVID-19 vaccine candidate on September 14.